Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma.
This report illustrates the potential diagnostic and therapeutic utility of somatostatin receptor scintigraphy and therapy with somatostatin. In-111 pentetreotide (In-111 octreotide), a somatostatin analog, was used to define the receptor status and the extent of disease in a case of malignant thymoma. Subsequent treatment with nonradioactive somatostatin inhibited tumor growth. In-111 octreotide may be useful to define tumor receptor status and may provide prognostic information useful in determining subsequent therapy.